Pharmacovigilance study on the reporting frequency of atrial fibrillation with immune checkpoint inhibitors: insights from FDA Adverse Event Reporting System

Pharmacovigilance study on the reporting frequency of atrial fibrillation with immune checkpoint inhibitors: insights from FDA Adverse Event Reporting System

Background: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are linked with immune-related adverse events (irAEs), including cardiac events. Objective: This study aims to assess the reporting frequency of atrial fibrillation with ICIs using data from the Food and Drug Adminis...

Full description

Saved in:

Bibliographic Details
Main Authors:	Nunzia Balzano, Annamaria Mascolo, Donatella Ruggiero, Concetta Rafaniello, Giuseppe Paolisso, Francesco Rossi, Annalisa Capuano
Format:	Article
Language:	English
Published:	SAGE Publishing 2025-04-01
Series:	Therapeutic Advances in Drug Safety
Online Access:	https://doi.org/10.1177/20420986241312497
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system
by: Yunhan Zhao, et al.
Published: (2025-05-01)

A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system
by: Miao Liu, et al.
Published: (2025-08-01)

The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yutong Wu, et al.
Published: (2025-05-01)

Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system
by: Chufeng Ding, et al.
Published: (2025-04-01)

Pharmacovigilance study of drug-induced eye movement disorder based on FDA adverse event reports from 2004 to 2024
by: Si-Yuan Hong, et al.
Published: (2025-07-01)

Drug-induced pulmonary edema: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS)
by: Zilan Zhong, et al.
Published: (2025-08-01)

Drug-induced sinusoidal obstruction syndrome: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System (FEARS)
by: Cuicui Sun, et al.
Published: (2025-07-01)

Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled Analysis
by: Asma Dilawari, et al.
Published: (2025-05-01)

A real-world pharmacovigilance analysis of ALK inhibitor-associated pleural and pericardial effusion using the FDA Adverse Events Reporting System (FAERS) database from 2013 to 2024.
by: Connor Frey
Published: (2025-01-01)

Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system
by: Yaqian Tan, et al.
Published: (2025-08-01)

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023
by: Saleh F. Alqifari, et al.
Published: (2025-07-01)

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Zhuomiao Lin, et al.
Published: (2025-08-01)

Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS)
by: Yuzhe Cheng, et al.
Published: (2025-01-01)

Causes of drug-induced photosensitivity: an analysis using FDA adverse event reporting system database
by: Lele Ge, et al.
Published: (2025-05-01)

Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS).
by: Yuzhe Cheng, et al.
Published: (2025-01-01)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for methimazole and propylthiouracil
by: Yun Li, et al.
Published: (2025-01-01)

Pharmacovigilance Data as a Trigger to Identify Antimicrobial Adverse Effects: A Study Using Reports from Basra Pharmacovigilance Centre
by: Sarah T Omran
Published: (2024-01-01)

Visualization of FDA Adverse Drug Reaction Reports: Development and Usability Study of the VisDrugs Web Server
by: Renjun Yang, et al.
Published: (2025-07-01)

A real-world data analysis of montelukast in FDA Adverse Event Reporting System (FAERS) database
by: Hesen Huang, et al.
Published: (2025-07-01)

Adverse events of pexidartinib for the treatment of TGCT: a real-world disproportionality analysis using FDA Adverse Event Reporting System database
by: Yu Lin, et al.
Published: (2025-08-01)

Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases
by: Tao Wang, et al.
Published: (2025-04-01)

An investigation of drug-induced mental disorders in the children and adolescents population utilizing the FDA adverse event reporting system
by: Linlin Tang, et al.
Published: (2025-07-01)

Knowledge, attitude, and practice among community pharmacists toward adverse drug reaction reporting and pharmacovigilance: A nationwide survey
by: Tahani Alwidyan, et al.
Published: (2025-06-01)

Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human iPS Cell‐Derived Cardiomyocytes and FDA Adverse Events Reporting System
by: Shota Yanagida, et al.
Published: (2025-08-01)

Adverse reactions of immune checkpoint inhibitors
by: E. R. Zagidullina, et al.
Published: (2025-06-01)

An integrated approach based on FDA adverse event reporting system, network pharmacology, molecular docking, and molecular dynamics simulation analysis to study the cardiac adverse reactions and mechanism of action of osimertinib
by: Wenjuan Wang, et al.
Published: (2025-06-01)

Cancer related adverse events associated with use of proton pump inhibitors and histamine-2 receptor antagonists: A real-world analysis using the FDA adverse event reporting system
by: Bowen Wang, et al.
Published: (2025-01-01)

A pharmacovigilance study of the association between linaclotide/plecanatide and muscle spasms based on food and drug administration adverse event reporting system
by: Xue Fan, et al.
Published: (2025-08-01)

Immune checkpoint inhibitor-associated myocarditis and pericarditis: a pharmacovigilance study based on the FAERS database
by: Guojing Yao, et al.
Published: (2025-08-01)

Adverse events associated with Implantable Collamer Lens: insights from the FDA MAUDE database
by: Qing Chen, et al.
Published: (2025-07-01)

Post-marketing safety surveillance of pneumococcal vaccines: a real-world pharmacovigilance study using the U.S. vaccine adverse event reporting system (VAERS) database
by: Xinkuo Zheng, et al.
Published: (2025-08-01)

Postmarketing adverse events associated with onasemnogene abeparvovec: a real-world pharmacovigilance study
by: Tianyu Chen, et al.
Published: (2025-05-01)

Association between antibody-dependent cellular cytotoxicity activity of antitumor antibodies and infusion reactions: a pharmacovigilance analysis using the Japanese adverse drug event report database
by: Yusuke Tabuchi, et al.
Published: (2025-08-01)

Retrieval and analysis of cyclopentolate hydrochloride eye drops related adverse drug reaction signals based on OpenFDA
by: WANG Jing, et al.
Published: (2025-04-01)

Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database
by: Zhenpo Zhang, et al.
Published: (2025-07-01)

Adverse Events Associated with Apremilast and Deucravacitinib for Psoriasis: A Pharmacovigilance Study Based on the FAERS Database
by: Xu Y, et al.
Published: (2025-05-01)

Disproportionality analysis of European safety reports on autoimmune and rheumatic diseases following COVID-19 vaccination
by: Federica Fraenza, et al.
Published: (2025-04-01)

Musculoskeletal adverse events reported post-hepatitis B vaccination in the vaccine adverse event reporting system
by: Yiqing Sun, et al.
Published: (2025-05-01)

Infective pneumonia following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: A real-world disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database
by: Qinhui Tang, et al.
Published: (2025-01-01)

Form of report on adverse drug reaction
by: Editorial Article
Published: (2018-02-01)